PCN123 BUDGET IMPACT ANALYSIS OF FIRST-LINE RIBOCICLIB IN THE TREATMENT OF PRE- AND POST-MENOPAUSAL WOMEN WITH HR+/HER2- ADVANCED OR METASTATIC BREAST CANCER IN THE UNITED STATES

Impact Analysis ◽

Budget Impact ◽

Metastatic Breast ◽

The United States ◽

First Line ◽

Menopausal Women ◽

Post Menopausal

PCN28 Budget Impact Analysis of Everolimus for ER+, HER2- Metastatic Breast Cancer Patients in the United States

Value in Health ◽

10.1016/j.jval.2012.03.1145 ◽

2012 ◽

Vol 15 (4) ◽

pp. A212

Author(s):

J. Xie ◽

M. Diener ◽

G. De ◽

E.Q. Wu ◽

M. Namjoshi

Keyword(s):

Breast Cancer ◽

United States ◽

Cancer Patients ◽

Impact Analysis ◽

Budget Impact ◽

Metastatic Breast ◽

The United States ◽

Budget Impact Analysis ◽

Breast Cancer Patients

Budget impact of including ribociclib in combination with letrozole on US payer formulary: first-line treatment of post-menopausal women with HR+/HER2− advanced or metastatic breast cancer

Current Medical Research and Opinion ◽

10.1080/03007995.2018.1503484 ◽

2018 ◽

Vol 34 (12) ◽

pp. 2143-2150 ◽

Cited By ~ 1

Author(s):

Rohit Mistry ◽

Gaurav Suri ◽

Kate Young ◽

Robert Hettle ◽

Jessica R. May ◽

...

Keyword(s):

Breast Cancer ◽

Budget Impact ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Menopausal Women ◽

Post Menopausal ◽

Abstract PS10-45: Budget impact of introducing neratinib for third-line treatment of HER2+ metastatic breast cancer in the United States

10.1158/1538-7445.sabcs20-ps10-45 ◽

2021 ◽

Author(s):

Seri AL Anderson ◽

Justin Carrico ◽

Thor-Henrik Brodtkorb ◽

Deepa Lalla ◽

Adam Brufsky

Keyword(s):

Breast Cancer ◽

United States ◽

Budget Impact ◽

Metastatic Breast ◽

The United States ◽

Line Treatment ◽

Third Line ◽

Third Line Treatment

PCN246 BUDGET IMPACT OF RIBOCICLIB PLUS LETROZOLE FOR THE TREATMENT OF POST-MENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE (HR+), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2- NEGATIVE (HER2-) ADVANCED OR METASTATIC BREAST CANCER IN DENMARK

Value in Health ◽

10.1016/j.jval.2019.09.441 ◽

2019 ◽

Vol 22 ◽

pp. S483

Author(s):

A.H. Møller ◽

L. Oddershede

Keyword(s):

Breast Cancer ◽

Epidermal Growth Factor Receptor ◽

Budget Impact ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Hormone Receptor Positive ◽

Menopausal Women ◽

Epidermal Growth ◽

Post Menopausal

481 An indirect comparison of aromatase inhibitors (AIs) in the first line treatment of post menopausal women with hormone receptor positive (HR+) metastatic breast cancer (MBC)

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(10)70502-4 ◽

2010 ◽

Vol 8 (3) ◽

pp. 200

Author(s):

J. Kleijnen ◽

R. Riemsma ◽

M.M. Amonkar ◽

K. Lykopoulos ◽

J.R. Diaz ◽

...

Keyword(s):

Breast Cancer ◽

Indirect Comparison ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Hormone Receptor Positive ◽

Menopausal Women ◽

Post Menopausal ◽

Abstract 891: Cost-effectiveness of CDK4/6 inhibitors in the first-line treatment of HR+/HER2- metastatic breast cancer in postmenopausal women in the United States

10.1158/1538-7445.am2021-891 ◽

2021 ◽

Author(s):

Prajakta P. Masurkar ◽

Haluk Damgacioglu ◽

Ashish Deshmukh ◽

Meghana Trivedi

Keyword(s):

Breast Cancer ◽

United States ◽

Cost Effectiveness ◽

Postmenopausal Women ◽

Metastatic Breast ◽

The United States ◽

Line Treatment ◽

First Line ◽

Estimated Life-Years Saved in Women with HER2-Positive Metastatic Breast Cancer Receiving First-Line Trastuzumab and Pertuzumab in the United States

Value in Health ◽

10.1016/j.jval.2015.06.003 ◽

2015 ◽

Vol 18 (6) ◽

pp. 876-883 ◽

Cited By ~ 4

Author(s):

Mark D. Danese ◽

Anthony Masaquel ◽

Eduardo Santos ◽

Melissa Brammer ◽

Abraham Lee ◽

...

Keyword(s):

Breast Cancer ◽

United States ◽

Metastatic Breast ◽

The United States ◽

First Line ◽

Her2 Positive ◽

Life Years

First-line treatment disruption among post-menopausal women with HR+/HER2– metastatic breast cancer: a retrospective US claims study

Current Medical Research and Opinion ◽

10.1080/03007995.2017.1390447 ◽

2017 ◽

Vol 33 (12) ◽

pp. 2137-2143 ◽

Cited By ~ 1

Author(s):

Derek H. Tang ◽

Nanxin Li ◽

Ella X. Du ◽

Miranda Peeples ◽

Lihao Chu ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Menopausal Women ◽

Post Menopausal ◽

Abstract PS11-21: First-line treatment trends in metastatic breast cancer before and at the early stage of the COVID-19 pandemic in the United States

10.1158/1538-7445.sabcs20-ps11-21 ◽

2021 ◽

Author(s):

Samantha Kurosky ◽

Xianchen Liu ◽

Aster Meche ◽

Rebecca Levin ◽

Amy Sullivan ◽

...

Keyword(s):

Breast Cancer ◽

United States ◽

Early Stage ◽

Metastatic Breast ◽

The United States ◽

Line Treatment ◽

First Line ◽

Treatment Trends ◽

Treatment patterns and real world clinical outcomes in ER+/HER2- post-menopausal metastatic breast cancer patients in the United States

BMC Cancer ◽

10.1186/s12885-017-3379-1 ◽

2017 ◽

Vol 17 (1) ◽

Cited By ~ 9

Author(s):

Giovanni Zanotti ◽

Matthias Hunger ◽

Julia J Perkins ◽

Ruslan Horblyuk ◽

Monique Martin

Keyword(s):

Breast Cancer ◽

United States ◽

Cancer Patients ◽

Real World ◽

Metastatic Breast ◽

The United States ◽

Treatment Patterns ◽

Breast Cancer Patients ◽

Post Menopausal